Patients with suspected prostate cancer need prostate biopsies to evaluate their cancer risk. Pre COVID-19, the standard of care for prostate biopsy practice has been outpatient transrectal biopsy (needle inserted via the rectum) under local anaesthetic. This method risks missed diagnosis, infection and sepsis.
Alternatively, transperineal (TP) biopsies (needle inserted through the perineal skin) provide more effective sampling and can virtually eliminate biopsy-related sepsis. However, they are impractical as a primary outpatient procedure because they require complex equipment and a general anaesthetic.
The PrecisionPointTM Transperineal Access System enables TP biopsies to be done without general anaesthetic. The novel needle guide allows for two simple punctures, which can be performed by trained nurses and radiographers in an outpatient setting. By enabling safer, more effective TP biopsies to be carried out under local anaesthetic, it transforms the prostate cancer pathway and improves the patient experience. Across the UK, transrectal biopsies are being abandoned in favour of TP biopsies and the associated savings through reduced use of general anaesthesia.